var data={"title":"Epidemiology and pathogenesis of amyotrophic lateral sclerosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Epidemiology and pathogenesis of amyotrophic lateral sclerosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/contributors\" class=\"contributor contributor_credentials\">Nicholas J Maragakis, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/contributors\" class=\"contributor contributor_credentials\">Nestor Galvez-Jimenez, MD, MSc, MHSA, FACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/contributors\" class=\"contributor contributor_credentials\">Jeremy M Shefner, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/contributors\" class=\"contributor contributor_credentials\">Ira N Targoff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/contributors\" class=\"contributor contributor_credentials\">April F Eichler, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 28, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amyotrophic lateral sclerosis (ALS), first described by Charcot in the nineteenth century [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/1\" class=\"abstract_t\">1</a>], is a relentlessly progressive neurodegenerative disorder that causes muscle weakness, disability, and eventually death, with a median survival of three to five years. ALS is also known by the eponym &quot;Lou Gehrig's Disease,&quot; after the famous baseball player who was affected with the disorder. Motor neuron disease (MND) is the preferred term in the United Kingdom, but in the United States ALS and MND are sometimes used interchangeably.</p><p>Historically, ALS was identified as a clinical syndrome distinguishable from other motor neuron diseases such as primary lateral sclerosis, primary muscular atrophy, and progressive bulbar palsy, based upon the location of first symptom and the extent to which anterior horn cells or corticomotor neurons are initially involved. However, it is increasingly evident that ALS is clinically and pathophysiologically diverse [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/2\" class=\"abstract_t\">2</a>], with clear overlap with frontotemporal dementia [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/3\" class=\"abstract_t\">3</a>]. Multiple genetic mutations may lead to a similar clinical phenotype, while a single mutation may be associated with pure ALS, ALS with frontotemporal dementia, or pure frontotemporal dementia. These conditions exist on a clinicopathologic spectrum, with potentially different etiologies that share a final common pathway leading to upper and lower motor neuron degeneration. It is therefore appropriate to place ALS among the neurodegenerative diseases, such as Alzheimer disease, Parkinson disease, and Huntington disease.</p><p>The epidemiology and pathogenesis of ALS are discussed in this topic review. Other aspects of ALS are discussed separately. (See <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;</a> and <a href=\"topic.htm?path=clinical-features-of-amyotrophic-lateral-sclerosis-and-other-forms-of-motor-neuron-disease\" class=\"medical medical_review\">&quot;Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-amyotrophic-lateral-sclerosis-and-other-forms-of-motor-neuron-disease\" class=\"medical medical_review\">&quot;Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amyotrophic lateral sclerosis (ALS) is classified as either sporadic or familial:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sporadic forms account for 90 to 95 percent of ALS cases.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Familial forms make up 5 to 10 percent of cases. (See <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Incidence and prevalence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Incidence rates for ALS in Europe and North America range between 1.5 and 2.7 per <span class=\"nowrap\">100,000/year,</span> while prevalence rates range between 2.7 and 7.4 per 100,000 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/4-7\" class=\"abstract_t\">4-7</a>]. In the United States, rates of ALS are higher among whites compared with blacks, Hispanics, and other races [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Similarly, a systematic review of global epidemiologic data concluded that the incidence of ALS may be lower among African, Asian, and Hispanic ethnic groups than among Caucasians [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/9\" class=\"abstract_t\">9</a>]. However, firm conclusions were precluded by the methodologic variation among studies that evaluated non-Caucasian populations.</p><p>The male to female ratio is about 1.3 to 1.5 for sporadic ALS, although the ratio becomes closer to unity in the age group over 70 years. The incidence of ALS increases with each decade, especially after age 40 years, and it peaks at age 74, decreasing thereafter [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/4\" class=\"abstract_t\">4</a>]. In a systematic review, the mean age of ALS onset was 62 years [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/10\" class=\"abstract_t\">10</a>]. In the United States, about 7000 new cases of ALS are diagnosed each year.</p><p>The incidence and mortality rates of ALS have been slowly increasing over decades [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/11-13\" class=\"abstract_t\">11-13</a>]. Part or all of this increase in ALS incidence may be due to longer life expectancy [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The only established risk factors for ALS are age and family history. Accumulating evidence suggests that cigarette smoking is also a risk factor for ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/15-17\" class=\"abstract_t\">15-17</a>]. The role of genetic variation in the pathogenesis of sporadic ALS is reviewed below. (See <a href=\"#H5\" class=\"local\">'Genetic susceptibility in sporadic ALS'</a> below.)</p><p>There are weaker or conflicting data for other putative risk factors, a list that includes military service, agricultural work, factory work, heavy manual labor, exposure to pesticides, exposure to welding or soldering, exposure to heavy metal, work in the plastics industry, repetitive muscle use, athleticism, playing professional soccer, trauma, electrical shock, early-onset alopecia, decreased premorbid body fat, and a diagnosis of polymyositis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/18-37\" class=\"abstract_t\">18-37</a>]. Paradoxically, other data suggest that mortality from ALS is increased among people with higher socioeconomic occupations (eg, education, computer and mathematical, legal, and architecture and engineering) where exposure to toxins is unlikely, while ALS mortality is decreased among people with lower socioeconomic occupations (eg, mining and drilling, construction, farming, fishing, and forestry) where exposure to toxins is more likely [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/38\" class=\"abstract_t\">38</a>].</p><p>Despite reports of exposure to mercury, lead, and aluminum in ALS cases [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/19,24\" class=\"abstract_t\">19,24</a>], the role of heavy metal exposure in the etiology of ALS remains controversial [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/25-27\" class=\"abstract_t\">25-27</a>]. No convincing case of lead toxicity mimicking ALS has been reported in several decades [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/25\" class=\"abstract_t\">25</a>].</p><p>The possible role of environmental exposure as an ALS trigger is supported by the finding that the incidence of ALS in young US Gulf War veterans is about a two-fold higher than expected [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/29,30\" class=\"abstract_t\">29,30</a>]. The risk ratio for developing ALS was statistically significant in Army and Air Force veterans, while a trend toward increased risk for veterans of the Reserves, National Guard, Marines, and Navy did not reach statistical significance, possibly because of the relatively small number of subjects in those branches. Despite the higher incidence among Gulf War veterans, no common link was identified among potential exposures or activities in veterans who developed ALS. Because ALS is a relatively rare disease, the strength of these findings is reduced by the small number of cases and potential methodological flaws [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/39\" class=\"abstract_t\">39</a>].</p><p>A subsequent, large cohort study of men (median age 57 years at cohort entry in 1982) found that US military veterans had an increased death rate from ALS compared with non-veterans (adjusted relative risk 1.58, 95% CI 1.14-2.19) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/31\" class=\"abstract_t\">31</a>]. As with previous studies, this higher incidence seemed independent of the branch of the military in which subjects served, except for the Marines, a subgroup with a small number of subjects. The increased risk of death from ALS was similar in veterans who served in the military during World War II, Korea, or Vietnam. There was no association between risk for developing ALS and the number of years served in the military. This result argues against a specific environmental trigger related to the Gulf War being a cause of ALS, since the association with ALS in the larger cohort study was largely independent of the time period of military service.</p><p>The potential risk factors that military personnel would share over the many decades of military service studied are numerous and include inhalation of aerosolized lead used in vehicle finishing operations, exposure to the pesticide DEET, traumatic injuries, viral infections, and intense physical activity. However, none of these are established as risk factors, and confirmation of these factors awaits further study.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Genetic susceptibility in sporadic ALS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Variations in a number of genes and loci appear to be associated with ALS susceptibility [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/40\" class=\"abstract_t\">40</a>]. The list includes known or suspected familial ALS genes, such as mutations in the SOD1, TARDBP, C9ORF72, FUS, ANG, OPTN, SETX, and SQSTM1 genes, and others not associated with familial ALS, such as mutations in the TBK1 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/41\" class=\"abstract_t\">41</a>], ATXN2 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/42\" class=\"abstract_t\">42</a>], C21ORF2 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/43\" class=\"abstract_t\">43</a>], ITPR2 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/44\" class=\"abstract_t\">44</a>], and NEK1 genes [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/45\" class=\"abstract_t\">45</a>], and duplications in the SMN1 gene [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/46\" class=\"abstract_t\">46</a>].</p><p>In a 2017 meta-analysis of 111 studies that evaluated the mutation frequencies of the most common ALS-related genes (C9ORF72, SOD1, TARDBP and FUS), there was a difference in mutation rates between European and Asian populations with sporadic ALS, as illustrated by the following observations [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/47\" class=\"abstract_t\">47</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In European populations, C9ORF72 repeat expansions were the most common (5.1 percent), followed by SOD1 mutations (1.2 percent), TARDBP mutations (0.8 percent), and FUS mutations (0.3 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In Asian populations, SOD1 mutations were the most common (1.5 percent), followed by FUS mutations (0.9 percent), C9ORF72 repeat expansions (0.3 percent), and TARDBP mutations (0.2 percent). </p><p/><p>An earlier study found that rare or novel coding variants in known ALS genes, potentially pathogenic though not proven to be, were present in 28 percent of subjects with sporadic ALS, while variants in more than one ALS gene were found in 4 percent [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/48\" class=\"abstract_t\">48</a>]. Thus, these genes may function as Mendelian genes in familial ALS or as low-penetrance susceptibility factors in sporadic ALS. (See <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;</a>.)</p><p>Some of the candidate genes for ALS are associated with other neurodegenerative disorders:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Expanded polyglutamine repeats in ATXN2 are better known as the cause of spinocerebellar ataxia type 2 (SCA2). One issue is that occasional patients with SCA2 have a predominant phenotype of motor neuron disease, and further study is needed to establish whether ATXN2 polyglutamine expansions are a risk factor for ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/49\" class=\"abstract_t\">49</a>]. (See <a href=\"topic.htm?path=the-spinocerebellar-ataxias#H6\" class=\"medical medical_review\">&quot;The spinocerebellar ataxias&quot;, section on 'SCA2'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The SMN gene is better known for its role in spinal muscular atrophy, a disease of neonatal or childhood onset characterized by degeneration of the anterior horn cells in the spinal cord and motor nuclei in the lower brainstem. (See <a href=\"topic.htm?path=spinal-muscular-atrophy\" class=\"medical medical_review\">&quot;Spinal muscular atrophy&quot;</a>.) &#160; </p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Familial ALS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Familial ALS accounts for 5 to 10 percent of all ALS cases [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/50\" class=\"abstract_t\">50</a>], with the rest being sporadic (idiopathic) in origin. Familial ALS is phenotypically and genetically heterogeneous. This topic is discussed separately. (See <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Geographic clusters</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>High prevalence clusters of ALS are found in three regions of the western Pacific including Guam, West New Guinea, and the Kii Peninsula in Japan. The first cluster described was found in the indigenous people of Guam [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/51,52\" class=\"abstract_t\">51,52</a>]. The frequent association of ALS with parkinsonism and Alzheimer disease in this population has led to the designation of this entity as the amyotrophic lateral sclerosis-parkinsonism dementia complex (ALS-PDC).</p><p>Although intensively studied since World War II, the cause of Guamanian ALS-PDC is unknown. One hypothesis proposed that the neurotoxicity was mediated by the local dietary consumption of cycad (Cycas circinalis) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/53\" class=\"abstract_t\">53</a>]. Cycad is rich in beta-N-methylamino-L-alanine (BMAA), an excitatory amino acid that has been shown to induce neuronal cell death in the rhesus monkey [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/53\" class=\"abstract_t\">53</a>]. Another hypothesis proposed that human consumption of the local flying fox, an animal that forages on the cycad, may have generated sufficiently high and cumulative levels of the neurotoxin to cause ALS-PDC. This hypothesis was supported by data demonstrating that the incidence of ALS-PDC on Guam fell significantly and in parallel with the loss of population of the flying fox [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/54\" class=\"abstract_t\">54</a>]. However, many remain unconvinced that cycad ingestion is the cause of Guamanian ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/55\" class=\"abstract_t\">55</a>]. No single genetic defect, environmental toxin, or virus has been convincingly linked to these cases.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amyotrophic lateral sclerosis (ALS) is characterized by motor neuron degeneration and death with gliosis replacing lost neurons. Cortical motor cells (pyramidal and Betz cells) disappear leading to retrograde axonal loss and gliosis in the corticospinal tract. This gliosis results in the bilateral white matter changes sometimes seen in the brain magnetic resonance imaging (MRI) of patients with ALS. The spinal cord becomes atrophic. The ventral roots become thin, and there is a loss of large myelinated fibers in motor nerves. The affected muscles show denervation atrophy with evidence of reinnervation such as fiber type grouping.</p><p>Additional pathologic findings may include a loss of frontal or temporal cortical neurons, particularly in ALS with frontotemporal dementia (ALS-FTD). Mounting evidence from pathologic and genetic studies has led to the hypothesis that similar molecular pathways are involved in both disorders. (See <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis#H1808661\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;, section on 'C9ORF72 gene'</a> and <a href=\"topic.htm?path=frontotemporal-dementia-epidemiology-pathology-and-pathogenesis#H10331476\" class=\"medical medical_review\">&quot;Frontotemporal dementia: Epidemiology, pathology, and pathogenesis&quot;, section on 'Genetic factors'</a>.)</p><p>Loss of non-motor neurons whose axons contribute to the descending fronto-ponto-cerebellar tract has been reported [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/56\" class=\"abstract_t\">56</a>]. Pathology in non-motor systems such as the posterior columns may be seen in familial forms of ALS. (See <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;</a>.)</p><p>While sensory involvement is not obvious clinically, the density of myelinated sensory fibers is reduced by approximately 30 percent in peripheral nerves [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/57\" class=\"abstract_t\">57</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Intracellular inclusions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intracellular inclusions in degenerating neurons and glia are frequent neuropathological findings of ALS.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Phosphorylated and nonphosphorylated neurofilament inclusions are prominent in spinal motor neurons; these may be associated with immunoreactive SOD1, even in sporadic ALS, or with nitric oxide.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bunina bodies are unique to ALS and consist of eosinophilic aggregates that are positive for cystatin C, a cysteine protease inhibitor.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ubiquinated inclusions are seen in ALS and several other neurodegenerative disorders, including frontotemporal dementia (FTD) with ubiquitin <span class=\"nowrap\">positive/tau</span> negative inclusions, but the ALS variety is unique in that it does not react with antibodies against neurofilament or tau. In both the familial or sporadic types of ALS-FTD, frontal and temporal lobe ubiquinated inclusions are found in cortical neurons. Inclusions may be absent in some genetic forms of FALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>TDP-43 accumulation and inclusion formation (ie, TDP-proteinopathy) is observed in most sporadic cases of ALS, frontotemporal dementia (FTD) with ubiquitin-positive but tau-negative inclusions (see <a href=\"topic.htm?path=frontotemporal-dementia-epidemiology-pathology-and-pathogenesis#H10210271\" class=\"medical medical_review\">&quot;Frontotemporal dementia: Epidemiology, pathology, and pathogenesis&quot;, section on 'FTLD-TDP'</a>), and overlapping ALS with frontotemporal dementia [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/59,60\" class=\"abstract_t\">59,60</a>]. In addition, TDP-43 neuronal cytoplasmic inclusions are found in familial ALS (see <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;</a>) related to mutations in a number of genes, which include the TARDBP gene that encodes for TDP-43, the VAPB gene, the CHMP2B gene, and to a lesser extent the C9ORF72 gene; in postmortem tissue from patients with C9ORF72 gene mutations, TDP-43 positive inclusions appear to be less common than TDP-43 negative inclusions containing ubiquitin [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/61\" class=\"abstract_t\">61</a>]. However, TDP-43 inclusions are not found in mutant SOD1-related familial ALS, with a few exceptions [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/62,63\" class=\"abstract_t\">62,63</a>]. These findings suggest a potentially important role for TDP-43 in the pathogenesis of ALS, non-SOD1 ALS, ALS-FTD, and non-tau FTD. (See <a href=\"#H107004749\" class=\"local\">'Altered RNA processing'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunoreactive inclusions to FUS in spinal motor neurons have been detected in both sporadic and familial ALS, with the exception of those associated with SOD1 mutations [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/64\" class=\"abstract_t\">64</a>]. The same inclusions were also immunoreactive with antibodies to TDP-43 and ubiquitin. Earlier studies had not detected FUS-positive immunoreactive inclusions in patients with ALS except for those who had FUS mutations.</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The etiology of amyotrophic lateral sclerosis (ALS) is unknown. A number of potential mechanisms have been proposed including abnormal RNA processing, SOD1-mediated toxicity, excitotoxicity, cytoskeletal derangements, mitochondrial dysfunction, viral infections, apoptosis, growth factor abnormalities, inflammatory responses, and others [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/65\" class=\"abstract_t\">65</a>].</p><p class=\"headingAnchor\" id=\"H107004749\"><span class=\"h2\">Altered RNA processing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mounting evidence supports the hypothesis that altered RNA processing and aggregation of abnormal proteins plays a major role in the pathogenesis of ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/66-69\" class=\"abstract_t\">66-69</a>]. Mutations in a number of genes that encode for RNA binding proteins, including TDP-43, FUS, HNRNPA2B1, and HNRNPA1, are known to cause ALS (see <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;</a>) and related neurodegenerative disorders. These proteins contain prion-like domains that have an intrinsic propensity to self-aggregation [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/70\" class=\"abstract_t\">70</a>]. They may normally function by assembling RNA into stress granules, which are temporary structures that help to regulate protein synthesis as part of the stress response [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/71\" class=\"abstract_t\">71</a>]. Mutations in the prion-like domains of these proteins may promote excess incorporation of the proteins into stress granules that are resistant to degradation, <span class=\"nowrap\">and/or</span> promote self-aggregation of abnormal RNA binding proteins (such as TDP-43), thereby leading to the formation of cytoplasmic inclusions (see <a href=\"#H9\" class=\"local\">'Intracellular inclusions'</a> above) and neurodegenerative disease. Another hypothesis is that TDP-43 normally functions by repressing the splicing of nonconserved regions of the genome known as cryptic exons [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/72\" class=\"abstract_t\">72</a>]. Depletion or aggregation of TDP-43 permits the splicing of cryptic exons into messenger RNA, which disrupts translation and leads to cell death. </p><p>The co-localization of TDP-43 and FUS in non-SOD1 ALS inclusions also supports the hypothesis that these <span class=\"nowrap\">DNA/RNA</span> binding proteins are involved in the pathogenesis of non-SOD1 forms of ALS. In-vitro studies indicate that mutant TDP-43 polypeptides have greater stability than those of the wild-type TDP-43 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/73\" class=\"abstract_t\">73</a>], rather than lesser stability as occurs with mutant SOD1. In addition, mutant TDP-43 shows enhanced binding to normal <span class=\"nowrap\">FUS/TLS</span>. These findings imply that mutant TDP-43 may disrupt normal <span class=\"nowrap\">FUS/TLS</span> function and suggest a convergence of their pathogenic mechanisms in ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/73\" class=\"abstract_t\">73</a>]. The TDP-43 and FUS proteins are normally found predominantly in the nucleus, where they are involved in RNA processing [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/66,67\" class=\"abstract_t\">66,67</a>]. Wild-type TDP-43 and FUS are transported to the nucleus by nuclear import receptors. However, mutant forms of TDP-43 with C-terminal truncations lack the nuclear transport signal, causing mislocalization of the protein to the cytoplasm. Similarly, ALS-associated FUS mutations impair nuclear transport and result in mislocalization to the cytoplasm. In sporadic ALS, aging may cause an accelerated increase in nuclear permeability and leakiness, with wild-type TDP-43 and FUS accumulating in the cytoplasm. The accumulation of TDP-43 and FUS in the cytoplasm may lead to neurodegeneration by disturbing the RNA quality control regulation or by the formation of stress granules (<a href=\"image.htm?imageKey=NEURO%2F64595\" class=\"graphic graphic_figure graphicRef64595 \">figure 1</a>).</p><p>The ALS susceptibility factor ataxin 2 (see <a href=\"#H5\" class=\"local\">'Genetic susceptibility in sporadic ALS'</a> above), a constituent of stress granules and a putative RNA binding protein, may interact in the common pathologic pathway formed by TDP-43 and FUS (<a href=\"image.htm?imageKey=NEURO%2F77362\" class=\"graphic graphic_figure graphicRef77362 \">figure 2</a>) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/66\" class=\"abstract_t\">66</a>]. In contrast, the pathologic process related to SOD1 mutations (see <a href=\"#H12\" class=\"local\">'SOD1-mediated toxicity'</a> below) may be independent of the TDP-43 and FUS pathologic cascade.</p><p class=\"headingAnchor\" id=\"H450667265\"><span class=\"h3\">C9ORF72 expansions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Expansion of a hexanucleotide repeat sequence in a noncoding region of the C9ORF72 gene is the most common genetic cause of familial ALS and is also detected in occasional patients with sporadic ALS. Several mechanisms may account for the disease-causing effect of the mutation [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/74\" class=\"abstract_t\">74</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The hexanucleotide repeat is made up of guanine-rich sequences, (GGGGCC)n, that can fold to form a secondary structure called a G-quadruplex [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/75\" class=\"abstract_t\">75</a>]. One hypothesis is that expansion of the hexanucleotide repeat sequence and G-quadruplex formation initiates a cascade of pathologic molecular alterations. These include formation of <span class=\"nowrap\">RNA/DNA</span> hybrids called R-loops, production of abortive, defective RNA transcripts, and decreased production of full-length RNA transcripts. The defective RNA transcripts bind to a number of ribonucleoproteins including nucleolin, causing mislocalization of this essential protein within the nucleolus and leading to decreased cell viability. The C9ORF72 hexanucleotide repeat expansion also interacts with Ran GTPase activating protein 1, which is an important regulator of nucleocytoplasmic transport, and may disrupt nucleocytoplasmic transport by clogging the nuclear membrane pores [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/76,77\" class=\"abstract_t\">76,77</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another hypothesis is that repeat-associated non-ATG translation (RAN translation) occurs within the expanded repeat sequence, leading to the production of toxic dipeptide repeat proteins that are aggregation-prone and can interfere with multiple steps of RNA processing [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/78-80\" class=\"abstract_t\">78-80</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The expansion may lead to reduced expression of C9orf72 protein levels, causing disease by a loss-of-function mechanism [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/81-83\" class=\"abstract_t\">81-83</a>].</p><p/><p>While not mutually exclusive, the contribution of each of these proposed mechanisms remains to be determined [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/74,84\" class=\"abstract_t\">74,84</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">SOD1-mediated toxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Superoxide dismutase type 1 (SOD1) is a metalloenzyme that catalyzes the conversion of toxic superoxide radicals to oxygen (O2) and hydrogen peroxide (H2O2). The discovery that mutations in the SOD1 gene are associated with some cases of familial ALS suggested that free radical toxicity may play a role in the process of neuronal cell death or apoptosis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/85\" class=\"abstract_t\">85</a>]. In addition, SOD1 mutations have been found in 0.7 to 4 percent of patients with &quot;sporadic&quot; ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/86,87\" class=\"abstract_t\">86,87</a>]. (See <a href=\"#H6\" class=\"local\">'Familial ALS'</a> above.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">Gain-of-function</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Damaging accumulation of superoxide could result if SOD1 mutations impaired its antioxidant function. However, several lines of evidence from cell culture and transgenic mutant SOD1 mouse models of ALS have disproved the loss-of-function hypothesis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/88,89\" class=\"abstract_t\">88,89</a>]. As an example, SOD1-knockout mice do not develop motor neuron disease [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/89\" class=\"abstract_t\">89</a>].</p><p>It is more likely that SOD1 mutations cause disease by a toxic gain-of-function [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/90\" class=\"abstract_t\">90</a>]. SOD1 has pro-oxidant as well as antioxidant activity, and mutated SOD1 could lead to oxidative injury by an increase in pro-oxidant pathways, including generation of hydroxyl radicals and nitration of tyrosine. In support of the toxic gain-of-function hypothesis, there is evidence that mutant SOD1 directly stimulates NADPH oxidase (Nox) in transgenic mice and in human cell lines, and thereby causes overproduction of reactive oxygen species [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/91,92\" class=\"abstract_t\">91,92</a>].</p><p>It has also been hypothesized that oxidation leads to post-translational modifications of wild-type SOD1, causing it to misfold and thereby gain toxic properties similar to mutant SOD1 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/93\" class=\"abstract_t\">93</a>]. This mechanism could then be the cause of the majority of cases of classic ALS, which lack SOD1 mutations.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Protein misfolding</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Another hypothesis is that mutant SOD1 induces protein aggregates that are potentially toxic to motor neurons [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/94,95\" class=\"abstract_t\">94,95</a>].</p><p>However, accumulation of disulfide cross-linked aggregates of mutant SOD1 may be a secondary manifestation of end-stage disease rather than a primary event in the pathogenesis of ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/96\" class=\"abstract_t\">96</a>]. This hypothesis is supported by a study in transgenic mice, which found that a number of pathologic abnormalities (eg, Golgi apparatus degradation, endplate denervation, reactive astrogliosis) occurred before the levels of aggregated forms of mutant SOD1 increased [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/96\" class=\"abstract_t\">96</a>]. The latter was observed only in the final stages of the disease.</p><p>Nevertheless, very low levels of SOD1 aggregates may be sufficient to mediate toxicity [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/96\" class=\"abstract_t\">96</a>]. Another possibility is that other forms of mutant SOD1 may be pathologic at early stages of disease. The initial step in the SOD protein assembly pathway is folding of the protein into a homodimeric apo state, and this apo-SOD1 protein is typically associated with severe instability in mutant SOD1 proteins [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/97\" class=\"abstract_t\">97</a>].</p><p>The conformational instability of ALS-linked SOD1 mutants may be related to reductional cleavage of the disulfide bond that normally links two cysteine subunits (C57-C146), resulting in an increased propensity of the protein to unfold or misfold and aggregate [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/98\" class=\"abstract_t\">98</a>]. More unstable and therefore short-lived mutants unfold and become prone to aggregation. In mice, unfolded or misfolded disulfide-reduced SOD1 mutants showed higher steady-state levels in the spinal cord and brain than in peripheral organs, suggesting inefficient recognition and degradation in the central nervous system [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/98\" class=\"abstract_t\">98</a>].</p><p>In a study that analyzed mutant SOD1 from 29 patients with 22 different mutations, lower levels (ie, greater instability) of mutant SOD1 were associated with shorter disease survival time [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/99\" class=\"abstract_t\">99</a>]. Thus, patients with less stable mutant SOD1 who accumulate less mutant protein have a more rapid disease course. However, levels of mutant SOD1 were not associated with age at disease onset.</p><p>These results suggest that the misfolded unstable forms of SOD1 contribute to toxicity and disease progression but not directly to onset, implying different mechanisms of disease onset and progression [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/100\" class=\"abstract_t\">100</a>]. Supporting this viewpoint is experimental evidence that suppressing mutant SOD1 synthesis selectively in motor neurons delays onset of disease in mice expressing mutant SOD1 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/101\" class=\"abstract_t\">101</a>].</p><p class=\"headingAnchor\" id=\"H28870207\"><span class=\"h3\">Non-neuronal cell types influence disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mutant SOD1 expression in non-neuronal cells may also be involved in the pathogenesis of ALS. Supporting evidence comes from studies in mutant SOD1 mice showing that cell types besides motor neurons play a role in disease onset and progression [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/102-105\" class=\"abstract_t\">102-105</a>]. In chimeric ALS mice, simple expression of the mutant SOD1 in <span class=\"nowrap\">neurons/motor</span> neurons was not sufficient to lead to neuronal death; there had to be concomitant expression in glia. Wild-type motor neurons appeared to undergo degeneration when surrounded by mutant SOD1 astroglia. Conversely, wild-type non-neuronal cells surrounding motor neurons expressing mutant SOD1 extended the survival of such motor neurons [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/102\" class=\"abstract_t\">102</a>] and increased disease-free life [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/106\" class=\"abstract_t\">106</a>]. Other reports demonstrated that the reduction of mutant SOD1 selectively from astrocytes in mice [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/104\" class=\"abstract_t\">104</a>] or in microglia [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/107\" class=\"abstract_t\">107</a>] resulted in a slowing of disease progression, but had no effects on disease onset. (See <a href=\"#H2160745\" class=\"local\">'Inflammatory responses'</a> below.)</p><p>These observations extend beyond the central nervous system, where evidence from a transgenic mouse model overexpressing the human SOD1 G93A mutation suggests that oxidative stress is present in skeletal muscle prior to motor neuron dropout and onset of symptomatic disease, as denoted by compensatory antioxidant enzyme upregulation [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/108\" class=\"abstract_t\">108</a>]. Skeletal muscle oxidative stress may adversely influence motor neuron survival via direct contact of motor neuron terminals with skeletal muscle and retrograde transport from skeletal muscle to motor neurons.</p><p class=\"headingAnchor\" id=\"H2160745\"><span class=\"h2\">Inflammatory responses</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A number of studies have shown that inflammatory processes are involved in ALS disease progression and neuronal death [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/107,109-115\" class=\"abstract_t\">107,109-115</a>]. These inflammatory responses include activation of microglia and astrocytes as well as infiltration of natural killer cells, peripheral T cells, and monocytes into the central nervous system (CNS). Many of these reports have focused on microglia, which are immune-modulating cells of the CNS. Once activated, microglia elaborate a host of factors, including nitric oxide, oxygen radicals, cytokines, glutamate, and others that may play roles in part of the cascade leading to motor neuron cell death [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/116\" class=\"abstract_t\">116</a>]. Several lines of evidence suggest that microglial activation is triggered by mutant SOD1 and contributes to neurodegeneration [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/92,116-118\" class=\"abstract_t\">92,116-118</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Excitotoxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The excitotoxicity hypothesis postulates that excessive levels of the excitatory neurotransmitter glutamate may initiate a cascade resulting in cellular death of motor neurons in ALS. Excessive activation of glutamate receptors may lead to increased entry of calcium into cells. In turn, intracellular calcium may trigger a cascade of events that causes neuronal cell death via lipid peroxidation, nucleic acid damage, and mitochondrial disruption.</p><p>The role of excitotoxicity in ALS remains unsettled. In support of the excitotoxicity hypothesis is the finding of elevated glutamate levels in the cerebrospinal fluid of patients with sporadic ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/119,120\" class=\"abstract_t\">119,120</a>]. In addition, defects in glutamate transport that may contribute to excessive extracellular glutamate have been noted in 80 percent of patients with sporadic ALS and in the transgenic mutant SOD1 mouse model of ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/121-123\" class=\"abstract_t\">121-123</a>]. These defects involve transmembrane glutamate transporters located on neurons and particularly on glial cells that are normally responsible for rapid inactivation of glutamate after its release.</p><p>One hypothesis suggests that non-functional, truncated forms of one glutamate transporter subtype (EAAT2), the primary glutamate transporter on astrocytes, may be particularly prominent in ALS tissues [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/121\" class=\"abstract_t\">121</a>]. However, some of these truncated forms have also been found in normal tissue. Additionally, it appears that a splice-variant of this protein (EAAT2b) may actually be upregulated in ALS, particularly in neurons. These findings suggest that there may be a potential compensatory effect to increase other glutamate transporters in the presence of elevated extracellular glutamate [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/124\" class=\"abstract_t\">124</a>].</p><p>Glutamate receptor dysfunction is another potential mechanism for excitotoxicity. A number of postsynaptic glutamate receptors may be involved in this process, including the N-methyl-D-aspartic acid (NMDA) receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor, the kainate receptor, and the G-protein-coupled receptor. As an example, defective editing of messenger RNA that encodes for a subunit of glutamate AMPA receptors has been found in spinal motor neurons of patients with ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/125\" class=\"abstract_t\">125</a>]. This glutamate editing defect has been linked to increased permeability to calcium ions through this AMPA receptor subtype and may result in downstream effects leading to neuronal death.</p><p>Deficiency in glutamate dehydrogenase activity may also lead to excitotoxicity; this has been demonstrated in some but not all studies [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/126\" class=\"abstract_t\">126</a>].</p><p>Perhaps some of the best evidence suggesting that glutamate excitotoxicity may have a role in ALS disease progression is the demonstration that the antiglutaminergic drug <a href=\"topic.htm?path=riluzole-drug-information\" class=\"drug drug_general\">riluzole</a> improves survival in patients with the disease. (See <a href=\"topic.htm?path=disease-modifying-treatment-of-amyotrophic-lateral-sclerosis#H2\" class=\"medical medical_review\">&quot;Disease-modifying treatment of amyotrophic lateral sclerosis&quot;, section on 'Riluzole'</a>.)</p><p>However, other drugs affecting glutamate neurotransmission have not been successful in clinical trials.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Cytoskeletal derangements</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The intracellular neurofilament inclusions found within degenerating motor neurons may be involved in the pathogenesis of ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/127,128\" class=\"abstract_t\">127,128</a>]. Neurofilaments are a type of intermediate filament expressed at high levels by motor neurons, and they are formed by the assembly of light, medium, and heavy subunits. They normally function as structural elements that perform vital roles in maintaining cell shape, axonal caliber, and axonal transport.</p><p>Deranged neurofilaments could disrupt axonal transport and cause axonal strangulation [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/129\" class=\"abstract_t\">129</a>]. Mutations in the neurofilament heavy subunit gene have been found in sporadic and familial forms of ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/130,131\" class=\"abstract_t\">130,131</a>]. Reduction in the light subunit mRNA levels was detected in spinal motor neurons of ALS patients [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/132\" class=\"abstract_t\">132</a>]. Overexpression or deletion of neurofilament subunits in transgenic mice resulted in motor neuron degeneration and axonal swellings with neurofilaments similar to those seen in ALS patients [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/129,133\" class=\"abstract_t\">129,133</a>].</p><p>Peripherin, an intermediate filament, is associated with neurofilaments in neuronal inclusions of patients with sporadic ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/134\" class=\"abstract_t\">134</a>]. Overexpression of peripherin in transgenic mice is associated with degeneration of motor axons, and inflammatory cytokines may increase peripherin levels [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/135\" class=\"abstract_t\">135</a>], suggesting a link between inflammation and ALS through interaction with peripherin [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/25\" class=\"abstract_t\">25</a>]. Whether the neurofilament inclusions seen in ALS are a cause or effect of neuronal degeneration is not yet settled [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/136\" class=\"abstract_t\">136</a>].</p><p>Inhibition of axonal transport may be a cause of motor neuron degeneration. Defects in the dynein-dynactin complex, a molecular motor responsible for axonal transport along microtubules, have been linked with motor degeneration in the mouse [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/137\" class=\"abstract_t\">137</a>], and a mutant dynactin has been linked with a progressive LMN disorder in a human family [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/138,139\" class=\"abstract_t\">138,139</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Mitochondrial dysfunction</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mitochondrial dysfunction occurs early in the transgenic mutant SOD1 mouse model, preceding other evidence of motor neuron damage [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/140\" class=\"abstract_t\">140</a>]. Data suggest that a selective recruitment of mutant SOD1 to spinal cord mitochondria, when compared with less affected tissues, may explain the abundant pathology in the spinal cord of the transgenic mutant SOD1 mouse [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/141\" class=\"abstract_t\">141</a>]. Human biochemical and morphologic studies demonstrate consistent mitochondrial abnormalities [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/142,143\" class=\"abstract_t\">142,143</a>]. These abnormalities may be the result of oxidative stress and, in turn, may potentiate it.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Viral infections</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Poliovirus, enteroviruses, and exogenous or inherited endogenous retroviruses, have been proposed to be causative agents of ALS [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/144-148\" class=\"abstract_t\">144-148</a>]. However, exhaustive studies have never confirmed a clear etiologic relationship. Human immunodeficiency virus (HIV) infection and Lyme disease rarely cause an ALS-like syndrome [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/149,150\" class=\"abstract_t\">149,150</a>]. (See <a href=\"topic.htm?path=polio-and-infectious-diseases-of-the-anterior-horn#H15\" class=\"medical medical_review\">&quot;Polio and infectious diseases of the anterior horn&quot;, section on 'Viruses and ALS-like syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Apoptosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Apoptosis or programmed cell death cascades have been implicated in several studies of the SOD1 mouse. These reports have shown a number of the hallmarks of apoptosis including DNA fragmentation, caspase activation, and altered expression of the antiapoptotic protein Bcl-2 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/94,151\" class=\"abstract_t\">94,151</a>]. Some evidence suggests that apoptosis may be a late pathway for motor neuron degeneration in ALS, but its importance in ALS has been controversial [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/152,153\" class=\"abstract_t\">152,153</a>]. However, one study found that genetic deletion of the mitochondrial apoptotic pathway in a mouse model of ALS halted neuronal loss and prevented axonal degeneration, symptom onset, and paralysis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/154\" class=\"abstract_t\">154</a>]. In addition, survival was extended. These findings suggest that inhibition of apoptosis is a possible therapeutic strategy for ALS.</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Growth factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Growth factors such as brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and insulin-like growth factor (IGF-1) have been studied previously both for their possible role in the etiology in ALS and for their therapeutic potential [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/155-158\" class=\"abstract_t\">155-158</a>].</p><p>The discovery that patients who have a specific haplotype for vascular endothelial growth factor (VEGF) may be more susceptible to ALS has increased enthusiasm for the possible role of growth factors in this disease [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/159,160\" class=\"abstract_t\">159,160</a>]. Additional attention to this growth factor is based on the finding that a cross between the VEGF knockout mouse and the transgenic mutant SOD1 mouse resulted in earlier death and more severe loss of motor neurons [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/159\" class=\"abstract_t\">159</a>]. Treatment of these animal models with VEGF in a number of different paradigms has resulted in significant improvement [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/161,162\" class=\"abstract_t\">161,162</a>], thus establishing VEGF as a potential candidate in ALS pathogenesis and targeting it for use in therapeutic studies.</p><p class=\"headingAnchor\" id=\"H28871029\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Amyotrophic lateral sclerosis (ALS) is classified as either sporadic or familial. Sporadic forms account for about 90 percent of ALS cases, while familial forms make up the remaining 10 percent. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above and <a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">&quot;Familial amyotrophic lateral sclerosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Incidence rates for ALS in Europe and North America range between 1.5 and 2.7 per <span class=\"nowrap\">100,000/year,</span> while prevalence rates range between 2.7 and 7.4 per 100,000. The male to female ratio is about 1.3 to 1.5 for sporadic ALS, although the ratio becomes closer to unity in the age group over 70 years. The incidence of ALS increases with each decade, especially after age 40 years. (See <a href=\"#H3\" class=\"local\">'Incidence and prevalence'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Established risk factors for ALS are age and family history. Accumulating evidence suggests that cigarette smoking is also a risk factor for ALS. There are weak or conflicting data for other putative nongenetic risk factors, a list that includes military service, agricultural work, factory work, heavy manual labor, exposure to welding or soldering, exposure to heavy metal, work in the plastics industry, repetitive muscle use, athleticism, playing professional soccer, trauma, and electrical shock. (See <a href=\"#H4\" class=\"local\">'Risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A number of genes that act as Mendelian genes in familial ALS (SOD1, C9ORF72, FUS, TARDBP, ANG, OPTN, and SETX) may also be low-penetrance susceptibility factors in sporadic ALS. Although not described in familial ALS, expansions in the ATXN2 gene and duplications of the SMN1 gene are associated with an increased risk of ALS. Current evidence suggests that there are additional low-risk genetic susceptibility loci for sporadic ALS awaiting confirmation <span class=\"nowrap\">and/or</span> discovery. (See <a href=\"#H5\" class=\"local\">'Genetic susceptibility in sporadic ALS'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>High prevalence clusters of ALS are found in three regions of the western Pacific including Guam, West New Guinea, and the Kii Peninsula in Japan. (See <a href=\"#H7\" class=\"local\">'Geographic clusters'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ALS is characterized by motor neuron degeneration and death with gliosis replacing lost neurons. Cortical motor cells (pyramidal and Betz cells) disappear, leading to retrograde axonal loss and gliosis in the corticospinal tract. The spinal cord becomes atrophic. The ventral roots become thin, and there is a loss of large myelinated fibers in motor nerves. The affected muscles show denervation atrophy with evidence of reinnervation such as fiber type grouping. Intracellular inclusions in degenerating neurons and glia are frequent neuropathological findings of ALS. (See <a href=\"#H8\" class=\"local\">'Pathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The etiology of ALS is not established. A number of mechanisms have been proposed, including abnormalities in RNA metabolism, SOD1-mediated toxicity, excitotoxicity, cytoskeletal derangements, mitochondrial dysfunction, viral infections, apoptosis, growth factor abnormalities, inflammatory responses, and others. (See <a href=\"#H11\" class=\"local\">'Etiology'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/1\" class=\"nounderline abstract_t\">Rowland LP. How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol 2001; 58:512.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/2\" class=\"nounderline abstract_t\">Turner MR, Swash M. The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. J Neurol Neurosurg Psychiatry 2015; 86:667.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/3\" class=\"nounderline abstract_t\">Turner MR, Hardiman O, Benatar M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013; 12:310.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/4\" class=\"nounderline abstract_t\">Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci 2001; 191:3.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/5\" class=\"nounderline abstract_t\">Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010; 81:385.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/6\" class=\"nounderline abstract_t\">Jordan H, Rechtman L, Wagner L, Kaye WE. Amyotrophic lateral sclerosis surveillance in Baltimore and Philadelphia. Muscle Nerve 2015; 51:815.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/7\" class=\"nounderline abstract_t\">Mehta P, Kaye W, Raymond J, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2014. MMWR Morb Mortal Wkly Rep 2018; 67:216.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/8\" class=\"nounderline abstract_t\">Roberts AL, Johnson NJ, Chen JT, et al. Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology 2016; 87:2300.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/9\" class=\"nounderline abstract_t\">Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology 2007; 68:1002.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/10\" class=\"nounderline abstract_t\">Chi&ograve; A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013; 41:118.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/11\" class=\"nounderline abstract_t\">Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence and distribution since 1950. J Neurol Neurosurg Psychiatry 1992; 55:1106.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/12\" class=\"nounderline abstract_t\">Noonan CW, White MC, Thurman D, Wong LY. Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998. Neurology 2005; 64:1215.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/13\" class=\"nounderline abstract_t\">Murphy M, Quinn S, Young J, et al. Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study. Neurology 2008; 71:1889.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/14\" class=\"nounderline abstract_t\">Chi&ograve; A, Magnani C, Schiffer D. Gompertzian analysis of amyotrophic lateral sclerosis mortality in Italy, 1957-1987; application to birth cohorts. Neuroepidemiology 1995; 14:269.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/15\" class=\"nounderline abstract_t\">Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology 2009; 73:1693.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/16\" class=\"nounderline abstract_t\">Gallo V, Bueno-De-Mesquita HB, Vermeulen R, et al. Smoking and risk for amyotrophic lateral sclerosis: analysis of the EPIC cohort. Ann Neurol 2009; 65:378.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/17\" class=\"nounderline abstract_t\">Sutedja NA, Veldink JH, Fischer K, et al. Lifetime occupation, education, smoking, and risk of ALS. Neurology 2007; 69:1508.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/18\" class=\"nounderline abstract_t\">Armon C, Kurland LT, Daube JR, O'Brien PC. Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology 1991; 41:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/19\" class=\"nounderline abstract_t\">Felmus MT, Patten BM, Swanke L. Antecedent events in amyotrophic lateral sclerosis. Neurology 1976; 26:167.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/20\" class=\"nounderline abstract_t\">Longstreth WT, McGuire V, Koepsell TD, et al. Risk of amyotrophic lateral sclerosis and history of physical activity: a population-based case-control study. Arch Neurol 1998; 55:201.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/21\" class=\"nounderline abstract_t\">Scarmeas N, Shih T, Stern Y, et al. Premorbid weight, body mass, and varsity athletics in ALS. Neurology 2002; 59:773.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/22\" class=\"nounderline abstract_t\">Chi&ograve; A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005; 128:472.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/23\" class=\"nounderline abstract_t\">Veldink JH, Kalmijn S, Groeneveld GJ, et al. Physical activity and the association with sporadic ALS. Neurology 2005; 64:241.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/24\" class=\"nounderline abstract_t\">Perl DP, Gajdusek DC, Garruto RM, et al. Intraneuronal aluminum accumulation in amyotrophic lateral sclerosis and Parkinsonism-dementia of Guam. Science 1982; 217:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/25\" class=\"nounderline abstract_t\">Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344:1688.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/26\" class=\"nounderline abstract_t\">Mitchell JD. Heavy metals and trace elements in amyotrophic lateral sclerosis. Neurol Clin 1987; 5:43.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/27\" class=\"nounderline abstract_t\">Kamel F, Umbach DM, Munsat TL, et al. Lead exposure and amyotrophic lateral sclerosis. Epidemiology 2002; 13:311.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/28\" class=\"nounderline abstract_t\">Gresham LS, Molgaard CA, Golbeck AL, Smith R. Amyotrophic lateral sclerosis and occupational heavy metal exposure: a case-control study. Neuroepidemiology 1986; 5:29.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/29\" class=\"nounderline abstract_t\">Haley RW. Excess incidence of ALS in young Gulf War veterans. Neurology 2003; 61:750.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/30\" class=\"nounderline abstract_t\">Horner RD, Kamins KG, Feussner JR, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 2003; 61:742.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/31\" class=\"nounderline abstract_t\">Weisskopf MG, O'Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology 2005; 64:32.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/32\" class=\"nounderline abstract_t\">Gallo V, Wark PA, Jenab M, et al. Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology 2013; 80:829.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/33\" class=\"nounderline abstract_t\">Fondell E, Fitzgerald KC, Falcone GJ, et al. Early-onset alopecia and amyotrophic lateral sclerosis: a cohort study. Am J Epidemiol 2013; 178:1146.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/34\" class=\"nounderline abstract_t\">Seals RM, Hansen J, Gredal O, Weisskopf MG. Physical Trauma and Amyotrophic Lateral Sclerosis: A Population-Based Study Using Danish National Registries. Am J Epidemiol 2016; 183:294.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/35\" class=\"nounderline abstract_t\">Eaglehouse YL, Talbott EO, Chang Y, Kuller LH. Participation in Physical Activity and Risk for Amyotrophic Lateral Sclerosis Mortality Among Postmenopausal Women. JAMA Neurol 2016; 73:329.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/36\" class=\"nounderline abstract_t\">Su FC, Goutman SA, Chernyak S, et al. Association of Environmental Toxins With Amyotrophic Lateral Sclerosis. JAMA Neurol 2016; 73:803.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/37\" class=\"nounderline abstract_t\">Tseng CC, Chang SJ, Tsai WC, et al. Increased Incidence of Amyotrophic Lateral Sclerosis in Polymyositis: A Nationwide Cohort Study. Arthritis Care Res (Hoboken) 2017; 69:1231.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/38\" class=\"nounderline abstract_t\">Beard JD, Steege AL, Ju J, et al. Mortality from Amyotrophic Lateral Sclerosis and Parkinson's Disease Among Different Occupation Groups - United States, 1985-2011. MMWR Morb Mortal Wkly Rep 2017; 66:718.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/39\" class=\"nounderline abstract_t\">Rose MR. Gulf War service is an uncertain trigger for ALS. Neurology 2003; 61:730.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/40\" class=\"nounderline abstract_t\">Leblond CS, Kaneb HM, Dion PA, Rouleau GA. Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp Neurol 2014; 262 Pt B:91.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/41\" class=\"nounderline abstract_t\">Cirulli ET, Lasseigne BN, Petrovski S, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015; 347:1436.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/42\" class=\"nounderline abstract_t\">Lattante S, Conte A, Zollino M, et al. Contribution of major amyotrophic lateral sclerosis genes to the etiology of sporadic disease. Neurology 2012; 79:66.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/43\" class=\"nounderline abstract_t\">van Rheenen W, Shatunov A, Dekker AM, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 2016; 48:1043.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/44\" class=\"nounderline abstract_t\">van Es MA, Van Vught PW, Blauw HM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol 2007; 6:869.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/45\" class=\"nounderline abstract_t\">Kenna KP, van Doormaal PT, Dekker AM, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 2016; 48:1037.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/46\" class=\"nounderline abstract_t\">Wang XB, Cui NH, Gao JJ, et al. SMN1 duplications contribute to sporadic amyotrophic lateral sclerosis susceptibility: evidence from a meta-analysis. J Neurol Sci 2014; 340:63.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/47\" class=\"nounderline abstract_t\">Zou ZY, Zhou ZR, Che CH, et al. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017; 88:540.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/48\" class=\"nounderline abstract_t\">Cady J, Allred P, Bali T, et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol 2015; 77:100.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/49\" class=\"nounderline abstract_t\">Fischbeck KH, Pulst SM. Amyotrophic lateral sclerosis and spinocerebellar ataxia 2. Neurology 2011; 76:2050.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/50\" class=\"nounderline abstract_t\">Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2011; 82:623.</a></li><li class=\"breakAll\">Zimmerman HM. Monthly report to the medical officer in command. United States Navy; Medical Research Unit No. 2, 1945.</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/52\" class=\"nounderline abstract_t\">KURLAND LT, MULDER DW. Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathologic observations. Neurology 1954; 4:355.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/53\" class=\"nounderline abstract_t\">Spencer PS, Nunn PB, Hugon J, et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987; 237:517.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/54\" class=\"nounderline abstract_t\">Cox PA, Sacks OW. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology 2002; 58:956.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/55\" class=\"nounderline abstract_t\">Steele JC, McGeer PL. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 2008; 70:1984.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/56\" class=\"nounderline abstract_t\">Parvizi J, Anderson SW, Martin CO, et al. Pathological laughter and crying: a link to the cerebellum. Brain 2001; 124:1708.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/57\" class=\"nounderline abstract_t\">Bradley WG, Good P, Rasool CG, Adelman LS. Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis. Ann Neurol 1983; 14:267.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/58\" class=\"nounderline abstract_t\">Arisato T, Okubo R, Arata H, et al. Clinical and pathological studies of familial amyotrophic lateral sclerosis (FALS) with SOD1 H46R mutation in large Japanese families. Acta Neuropathol 2003; 106:561.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/59\" class=\"nounderline abstract_t\">Geser F, Martinez-Lage M, Robinson J, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009; 66:180.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/60\" class=\"nounderline abstract_t\">Ince PG, Highley JR, Kirby J, et al. Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol 2011; 122:657.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/61\" class=\"nounderline abstract_t\">Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol 2012; 11:54.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/62\" class=\"nounderline abstract_t\">Okamoto Y, Ihara M, Urushitani M, et al. An autopsy case of SOD1-related ALS with TDP-43 positive inclusions. Neurology 2011; 77:1993.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/63\" class=\"nounderline abstract_t\">Sumi H, Kato S, Mochimaru Y, et al. Nuclear TAR DNA binding protein 43 expression in spinal cord neurons correlates with the clinical course in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2009; 68:37.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/64\" class=\"nounderline abstract_t\">Deng HX, Zhai H, Bigio EH, et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 2010; 67:739.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/65\" class=\"nounderline abstract_t\">Peters OM, Ghasemi M, Brown RH Jr. Emerging mechanisms of molecular pathology in ALS. J Clin Invest 2015; 125:1767.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/66\" class=\"nounderline abstract_t\">Ito D, Suzuki N. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. Neurology 2011; 77:1636.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/67\" class=\"nounderline abstract_t\">Buratti E. TDP-43 and FUS in ALS/FTLD: will common pathways fit all? Neurology 2011; 77:1588.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/68\" class=\"nounderline abstract_t\">Verma A, Tandan R. RNA quality control and protein aggregates in amyotrophic lateral sclerosis: a review. Muscle Nerve 2013; 47:330.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/69\" class=\"nounderline abstract_t\">Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013; 495:467.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/70\" class=\"nounderline abstract_t\">Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011; 147:498.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/71\" class=\"nounderline abstract_t\">Wolozin B. Regulated protein aggregation: stress granules and neurodegeneration. Mol Neurodegener 2012; 7:56.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/72\" class=\"nounderline abstract_t\">Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science 2015; 349:650.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/73\" class=\"nounderline abstract_t\">Ling SC, Albuquerque CP, Han JS, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A 2010; 107:13318.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/74\" class=\"nounderline abstract_t\">Heutink P, Jansen IE, Lynes EM. C9orf72; abnormal RNA expression is the key. Exp Neurol 2014; 262 Pt B:102.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/75\" class=\"nounderline abstract_t\">Haeusler AR, Donnelly CJ, Periz G, et al. C9orf72 nucleotide repeat structures initiate molecular cascades of disease. Nature 2014; 507:195.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/76\" class=\"nounderline abstract_t\">Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 2015; 525:56.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/77\" class=\"nounderline abstract_t\">Underwood E. NEUROSCIENCE. Plugged pores may underlie some ALS, dementia cases. Science 2015; 349:911.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/78\" class=\"nounderline abstract_t\">Kwon I, Xiang S, Kato M, et al. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 2014; 345:1139.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/79\" class=\"nounderline abstract_t\">Mizielinska S, Gr&ouml;nke S, Niccoli T, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 2014; 345:1192.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/80\" class=\"nounderline abstract_t\">Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013; 339:1335.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/81\" class=\"nounderline abstract_t\">Belzil VV, Bauer PO, Prudencio M, et al. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol 2013; 126:895.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/82\" class=\"nounderline abstract_t\">Ciura S, Lattante S, Le Ber I, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol 2013; 74:180.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/83\" class=\"nounderline abstract_t\">Waite AJ, B&auml;umer D, East S, et al. Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging 2014; 35:1779.e5.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/84\" class=\"nounderline abstract_t\">Paul JW, Gitler AD. Cell Biology. Clogging information flow in ALS. Science 2014; 345:1118.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/85\" class=\"nounderline abstract_t\">Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362:59.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/86\" class=\"nounderline abstract_t\">Andersen PM. Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr Neurol Neurosci Rep 2006; 6:37.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/87\" class=\"nounderline abstract_t\">Chi&ograve; A, Traynor BJ, Lombardo F, et al. Prevalence of SOD1 mutations in the Italian ALS population. Neurology 2008; 70:533.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/88\" class=\"nounderline abstract_t\">Gurney ME. Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994; 331:1721.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/89\" class=\"nounderline abstract_t\">Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13:43.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/90\" class=\"nounderline abstract_t\">Gurney ME. Transgenic animal models of familial amyotrophic lateral sclerosis. J Neurol 1997; 244 Suppl 2:S15.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/91\" class=\"nounderline abstract_t\">Harraz MM, Marden JJ, Zhou W, et al. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest 2008; 118:659.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/92\" class=\"nounderline abstract_t\">Boill&eacute;e S, Cleveland DW. Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1. J Clin Invest 2008; 118:474.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/93\" class=\"nounderline abstract_t\">Kabashi E, Valdmanis PN, Dion P, Rouleau GA. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann Neurol 2007; 62:553.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/94\" class=\"nounderline abstract_t\">Durham HD, Roy J, Dong L, Figlewicz DA. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997; 56:523.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/95\" class=\"nounderline abstract_t\">Cleveland DW, Liu J. Oxidation versus aggregation - how do SOD1 mutants cause ALS? Nat Med 2000; 6:1320.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/96\" class=\"nounderline abstract_t\">Karch CM, Prudencio M, Winkler DD, et al. Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc Natl Acad Sci U S A 2009; 106:7774.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/97\" class=\"nounderline abstract_t\">Lindberg MJ, Tibell L, Oliveberg M. Common denominator of Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis: decreased stability of the apo state. Proc Natl Acad Sci U S A 2002; 99:16607.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/98\" class=\"nounderline abstract_t\">Jonsson PA, Graffmo KS, Andersen PM, et al. Disulphide-reduced superoxide dismutase-1 in CNS of transgenic amyotrophic lateral sclerosis models. Brain 2006; 129:451.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/99\" class=\"nounderline abstract_t\">Sato T, Nakanishi T, Yamamoto Y, et al. Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology 2005; 65:1954.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/100\" class=\"nounderline abstract_t\">Yamanaka K, Cleveland DW. Determinants of rapid disease progression in ALS. Neurology 2005; 65:1859.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/101\" class=\"nounderline abstract_t\">Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005; 11:429.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/102\" class=\"nounderline abstract_t\">Clement AM, Nguyen MD, Roberts EA, et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003; 302:113.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/103\" class=\"nounderline abstract_t\">Borchelt DR. Amyotrophic lateral sclerosis--are microglia killing motor neurons? N Engl J Med 2006; 355:1611.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/104\" class=\"nounderline abstract_t\">Yamanaka K, Chun SJ, Boillee S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008; 11:251.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/105\" class=\"nounderline abstract_t\">Kang SH, Li Y, Fukaya M, et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci 2013; 16:571.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/106\" class=\"nounderline abstract_t\">Yamanaka K, Boillee S, Roberts EA, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci U S A 2008; 105:7594.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/107\" class=\"nounderline abstract_t\">Boill&eacute;e S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006; 312:1389.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/108\" class=\"nounderline abstract_t\">Mahoney DJ, Kaczor JJ, Bourgeois J, et al. Oxidative stress and antioxidant enzyme upregulation in SOD1-G93A mouse skeletal muscle. Muscle Nerve 2006; 33:809.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/109\" class=\"nounderline abstract_t\">Neusch C, B&auml;hr M, Schneider-Gold C. Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease? Muscle Nerve 2007; 35:712.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/110\" class=\"nounderline abstract_t\">Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 2011; 10:253.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/111\" class=\"nounderline abstract_t\">Beers DR, Henkel JS, Zhao W, et al. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci U S A 2008; 105:15558.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/112\" class=\"nounderline abstract_t\">Lincecum JM, Vieira FG, Wang MZ, et al. From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet 2010; 42:392.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/113\" class=\"nounderline abstract_t\">Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10:615.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/114\" class=\"nounderline abstract_t\">Butovsky O, Siddiqui S, Gabriely G, et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 2012; 122:3063.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/115\" class=\"nounderline abstract_t\">Frakes AE, Ferraiuolo L, Haidet-Phillips AM, et al. Microglia induce motor neuron death via the classical NF-&kappa;B pathway in amyotrophic lateral sclerosis. Neuron 2014; 81:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/116\" class=\"nounderline abstract_t\">Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23:249.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/117\" class=\"nounderline abstract_t\">Zhao W, Beers DR, Henkel JS, et al. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 2010; 58:231.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/118\" class=\"nounderline abstract_t\">Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci U S A 2010; 107:13046.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/119\" class=\"nounderline abstract_t\">Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28:18.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/120\" class=\"nounderline abstract_t\">Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995; 4:209.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/121\" class=\"nounderline abstract_t\">Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998; 20:589.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/122\" class=\"nounderline abstract_t\">Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38:73.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/123\" class=\"nounderline abstract_t\">Dunlop J, Beal McIlvain H, She Y, Howland DS. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. J Neurosci 2003; 23:1688.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/124\" class=\"nounderline abstract_t\">Maragakis NJ, Dykes-Hoberg M, Rothstein JD. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann Neurol 2004; 55:469.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/125\" class=\"nounderline abstract_t\">Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004; 427:801.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/126\" class=\"nounderline abstract_t\">Pioro EP, Majors AW, Mitsumoto H, et al. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology 1999; 53:71.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/127\" class=\"nounderline abstract_t\">Morrison BM, Morrison JH, Gordon JW. Superoxide dismutase and neurofilament transgenic models of amyotrophic lateral sclerosis. J Exp Zool 1998; 282:32.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/128\" class=\"nounderline abstract_t\">Lin H, Schlaepfer WW. Role of neurofilament aggregation in motor neuron disease. Ann Neurol 2006; 60:399.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/129\" class=\"nounderline abstract_t\">Collard JF, C&ocirc;t&eacute; F, Julien JP. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature 1995; 375:61.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/130\" class=\"nounderline abstract_t\">Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet 1994; 3:1757.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/131\" class=\"nounderline abstract_t\">Al-Chalabi A, Andersen PM, Nilsson P, et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8:157.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/132\" class=\"nounderline abstract_t\">Wong NK, He BP, Strong MJ. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J Neuropathol Exp Neurol 2000; 59:972.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/133\" class=\"nounderline abstract_t\">C&ocirc;t&eacute; F, Collard JF, Julien JP. Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: a mouse model of amyotrophic lateral sclerosis. Cell 1993; 73:35.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/134\" class=\"nounderline abstract_t\">Corbo M, Hays AP. Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J Neuropathol Exp Neurol 1992; 51:531.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/135\" class=\"nounderline abstract_t\">Sterneck E, Kaplan DR, Johnson PF. Interleukin-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells. J Neurochem 1996; 67:1365.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/136\" class=\"nounderline abstract_t\">Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci 2000; 180:7.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/137\" class=\"nounderline abstract_t\">LaMonte BH, Wallace KE, Holloway BA, et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002; 34:715.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/138\" class=\"nounderline abstract_t\">Puls I, Jonnakuty C, LaMonte BH, et al. Mutant dynactin in motor neuron disease. Nat Genet 2003; 33:455.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/139\" class=\"nounderline abstract_t\">Puls I, Oh SJ, Sumner CJ, et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol 2005; 57:687.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/140\" class=\"nounderline abstract_t\">Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 1998; 18:3241.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/141\" class=\"nounderline abstract_t\">Liu J, Lillo C, Jonsson PA, et al. Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria. Neuron 2004; 43:5.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/142\" class=\"nounderline abstract_t\">Cassarino DS, Bennett JP Jr. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res Brain Res Rev 1999; 29:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/143\" class=\"nounderline abstract_t\">Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58:495.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/144\" class=\"nounderline abstract_t\">Swanson NR, Fox SA, Mastaglia FL. Search for persistent infection with poliovirus or other enteroviruses in amyotrophic lateral sclerosis-motor neurone disease. Neuromuscul Disord 1995; 5:457.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/145\" class=\"nounderline abstract_t\">Nix WA, Berger MM, Oberste MS, et al. Failure to detect enterovirus in the spinal cord of ALS patients using a sensitive RT-PCR method. Neurology 2004; 62:1372.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/146\" class=\"nounderline abstract_t\">Jubelt B, Lipton HL. ALS: persistent scientists do not find persisting enteroviruses. Neurology 2004; 62:1250.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/147\" class=\"nounderline abstract_t\">Steele AJ, Al-Chalabi A, Ferrante K, et al. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology 2005; 64:454.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/148\" class=\"nounderline abstract_t\">McCormick AL, Brown RH Jr, Cudkowicz ME, et al. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology 2008; 70:278.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/149\" class=\"nounderline abstract_t\">Halperin JJ. Nervous system Lyme disease. J Neurol Sci 1998; 153:182.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/150\" class=\"nounderline abstract_t\">Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. Neurology 2001; 57:995.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/151\" class=\"nounderline abstract_t\">Spooren WP, Hengerer B. DNA laddering and caspase 3-like activity in the spinal cord of a mouse model of familial amyotrophic lateral sclerosis. Cell Mol Biol (Noisy-le-grand) 2000; 46:63.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/152\" class=\"nounderline abstract_t\">Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58:459.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/153\" class=\"nounderline abstract_t\">He BP, Strong MJ. Motor neuronal death in sporadic amyotrophic lateral sclerosis (ALS) is not apoptotic. A comparative study of ALS and chronic aluminium chloride neurotoxicity in New Zealand white rabbits. Neuropathol Appl Neurobiol 2000; 26:150.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/154\" class=\"nounderline abstract_t\">Reyes NA, Fisher JK, Austgen K, et al. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest 2010; 120:3673.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/155\" class=\"nounderline abstract_t\">A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 1999; 52:1427.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/156\" class=\"nounderline abstract_t\">Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol 1996; 39:256.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/157\" class=\"nounderline abstract_t\">Lai EC, Felice KJ, Festoff BW, et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49:1621.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/158\" class=\"nounderline abstract_t\">Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51:583.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/159\" class=\"nounderline abstract_t\">Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003; 34:383.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/160\" class=\"nounderline abstract_t\">Terry PD, Kamel F, Umbach DM, et al. VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). J Neurogenet 2004; 18:429.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/161\" class=\"nounderline abstract_t\">Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429:413.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-amyotrophic-lateral-sclerosis/abstract/162\" class=\"nounderline abstract_t\">Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8:85.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5156 Version 37.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H28871029\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Incidence and prevalence</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Risk factors</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Genetic susceptibility in sporadic ALS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Familial ALS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Geographic clusters</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">PATHOLOGY</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Intracellular inclusions</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">ETIOLOGY</a><ul><li><a href=\"#H107004749\" id=\"outline-link-H107004749\">Altered RNA processing</a><ul><li><a href=\"#H450667265\" id=\"outline-link-H450667265\">- C9ORF72 expansions</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">SOD1-mediated toxicity</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- Gain-of-function</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Protein misfolding</a></li><li><a href=\"#H28870207\" id=\"outline-link-H28870207\">- Non-neuronal cell types influence disease</a></li></ul></li><li><a href=\"#H2160745\" id=\"outline-link-H2160745\">Inflammatory responses</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Excitotoxicity</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Cytoskeletal derangements</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Mitochondrial dysfunction</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">Viral infections</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">Apoptosis</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Growth factors</a></li></ul></li><li><a href=\"#H28871029\" id=\"outline-link-H28871029\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"NEURO/5156|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/64595\" class=\"graphic graphic_figure\">- Hypothetical pathology TDP-43 and FUS proteinopathy</a></li><li><a href=\"image.htm?imageKey=NEURO/77362\" class=\"graphic graphic_figure\">- Possible pathologic cascade ALS and FTLD-linked molecules</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-of-amyotrophic-lateral-sclerosis-and-other-forms-of-motor-neuron-disease\" class=\"medical medical_review\">Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-amyotrophic-lateral-sclerosis-and-other-forms-of-motor-neuron-disease\" class=\"medical medical_review\">Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=disease-modifying-treatment-of-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">Disease-modifying treatment of amyotrophic lateral sclerosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=familial-amyotrophic-lateral-sclerosis\" class=\"medical medical_review\">Familial amyotrophic lateral sclerosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=frontotemporal-dementia-epidemiology-pathology-and-pathogenesis\" class=\"medical medical_review\">Frontotemporal dementia: Epidemiology, pathology, and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=polio-and-infectious-diseases-of-the-anterior-horn\" class=\"medical medical_review\">Polio and infectious diseases of the anterior horn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=spinal-muscular-atrophy\" class=\"medical medical_review\">Spinal muscular atrophy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-spinocerebellar-ataxias\" class=\"medical medical_review\">The spinocerebellar ataxias</a></li></ul></div></div>","javascript":null}